Conditions: Alopecia Areata Alopecia Totalis Alopecia Universalis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 40
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Detailed description:
This study is an open-label pilot study. Participants will be treated with oral tofacitinib for 3 months.

Arms:
arm 1: Participants will receive tofacitinib for 3 months.

Interventions: intervention 1: Tofacitinib
Intervention descriptions: intervention 1: Tofacitinib 5 mg tablet taken by mouth twice a day.

Protocol document: